Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to -$402000.0.

  • Lifecore Biomedical, Inc. \De\'s Cash from Financing Activities rose 3452.77% to -$402000.0 in Q2 2025 from the same period last year, while for May 2025 it was $6.4 million, marking a year-over-year decrease of 1444.93%. This contributed to the annual value of $6.4 million for FY2025, which is 1444.93% down from last year.
  • Lifecore Biomedical, Inc. \De\'s Cash from Financing Activities amounted to -$402000.0 in Q2 2025, which was up 3452.77% from -$6.8 million recorded in Q1 2025.
  • Lifecore Biomedical, Inc. \De\'s 5-year Cash from Financing Activities high stood at $24.6 million for Q2 2023, and its period low was -$47.1 million during Q1 2022.
  • For the 5-year period, Lifecore Biomedical, Inc. \De\'s Cash from Financing Activities averaged around $843833.3, with its median value being $3.4 million (2022).
  • As far as peak fluctuations go, Lifecore Biomedical, Inc. \De\'s Cash from Financing Activities crashed by 50635.95% in 2022, and later soared by 61123.37% in 2024.
  • Quarter analysis of 5 years shows Lifecore Biomedical, Inc. \De\'s Cash from Financing Activities stood at $9.9 million in 2021, then fell by 10.82% to $8.8 million in 2022, then crashed by 127.79% to -$2.4 million in 2023, then surged by 611.23% to $12.5 million in 2024, then plummeted by 103.21% to -$402000.0 in 2025.
  • Its last three reported values are -$402000.0 in Q2 2025, -$6.8 million for Q1 2025, and $12.5 million during Q4 2024.